Infliximab News and Research

RSS
Infliximab is a monoclonal antibody that blocks the action of a cytokine called tumor necrosis factor alfa. It is being studied in the treatment and prevention of weight loss and loss of appetite in patients with advanced cancer. It belongs to the family of drugs called monoclonal antibodies.
New treatment guidelines published for anorectal abscess, anal fistula, and rectovaginal fistula

New treatment guidelines published for anorectal abscess, anal fistula, and rectovaginal fistula

Risk of severe COVID-19 in adults with immune-mediated inflammatory diseases and those on immune-modifying therapies

Risk of severe COVID-19 in adults with immune-mediated inflammatory diseases and those on immune-modifying therapies

Immune modulator drugs improved clinical status, reduced deaths among patients hospitalized with COVID-19

Immune modulator drugs improved clinical status, reduced deaths among patients hospitalized with COVID-19

Two cases of MIS-C after laboratory-confirmed SARS-CoV-2 breakthrough infections in fully vaccinated adolescent patients

Two cases of MIS-C after laboratory-confirmed SARS-CoV-2 breakthrough infections in fully vaccinated adolescent patients

Gut microbiota linked to immunocompromised people's variable response to SARS-CoV-2 vaccination

Gut microbiota linked to immunocompromised people's variable response to SARS-CoV-2 vaccination

New insight into lymphoid cell maturity could pave the way for more effective IBD treatments

New insight into lymphoid cell maturity could pave the way for more effective IBD treatments

Heart complications uncommon for children and young adults after SARS-CoV-2 infection

Heart complications uncommon for children and young adults after SARS-CoV-2 infection

Study explores COVID-19 vaccine effectiveness in ankylosing spondylitis patients

Study explores COVID-19 vaccine effectiveness in ankylosing spondylitis patients

Trial identifies a drug that may benefit some patients hospitalized with COVID-19 pneumonia

Trial identifies a drug that may benefit some patients hospitalized with COVID-19 pneumonia

People taking immunosuppressant produce weaker, shorter-lived antibodies after COVID-19 vaccination

People taking immunosuppressant produce weaker, shorter-lived antibodies after COVID-19 vaccination

Immune response elicited by SARS-CoV-2 vaccines in infliximab and vedolizumab-treated patients with IBD

Immune response elicited by SARS-CoV-2 vaccines in infliximab and vedolizumab-treated patients with IBD

Studies test intravenous immunoglobulin for treatment of Kawasaki disease and MIS-C

Studies test intravenous immunoglobulin for treatment of Kawasaki disease and MIS-C

Can targeting autophagy become a new approach to COVID-19 treatment?

Can targeting autophagy become a new approach to COVID-19 treatment?

Real-world data sheds new light on biologic treatment and vaccine hesitancy in psoriasis patients

Real-world data sheds new light on biologic treatment and vaccine hesitancy in psoriasis patients

Dual therapy improves cardiac outcomes in pediatric patients suffering from MIS-C

Dual therapy improves cardiac outcomes in pediatric patients suffering from MIS-C

Humoral and cellular response to COVID-19 vaccines in patients with IBD

Humoral and cellular response to COVID-19 vaccines in patients with IBD

Commonly-prescribed drug for IBD blunts COVID-19 vaccine response

Commonly-prescribed drug for IBD blunts COVID-19 vaccine response

Infliximab may hinder the effectiveness of some COVID-19 vaccines

Infliximab may hinder the effectiveness of some COVID-19 vaccines

Researchers launch clinical trial to assess therapeutic drug monitoring for patients with inflammatory diseases

Researchers launch clinical trial to assess therapeutic drug monitoring for patients with inflammatory diseases

NIH launches adaptive Phase 3 clinical trial to test immune modulator drugs in COVID-19 patients

NIH launches adaptive Phase 3 clinical trial to test immune modulator drugs in COVID-19 patients